Los Angeles, United States, July 16th, 2026, FinanceWire

Proven on US$20M in Philippine SME loans with a sub-3% NPL rate, Jia’s AI underwriting infrastructure Ossicone is now available for banks, cooperatives and lending companies to deploy under their own brand 

Jia, a financial platform serving businesses across emerging markets, today announced a landmark partnership with Netbank, a bank regulated by the Bangko Sentral ng Pilipinas, marking the first time Jia has opened its lending infrastructure to an outside institution. As part of the partnership, Netbank has extended Jia a $2 million credit facility, Jia’s first institutional credit facility in the Philippines, to fund working capital loans for up to 500 SMEs over the next 12 months, and is powering Jia Accounts, a new business banking product for Philippine SMEs that lets borrowers receive funds and manage repayments in a single regulated flow

The partnership is the latest milestone in Jia’s expansion from lender to platform. Since 2022, Jia has originated more than US$20 million in SME loans in the Philippines with a non-performing loan rate below 3% and zero write-offs, against an industry average of 10% to 15%. That track record was built lending to the businesses most institutions overlook such as retailers, distributors, and inventory-heavy companies with proven order flow and a history of repayment, underserved not by their own performance but by the limitations of conventional credit assessment.

At the center of Jia’s infrastructure is Ossicone, its proprietary AI underwriting engine. Ossicone reads the documents that define how emerging market businesses actually operate – purchase orders, supplier invoices, delivery receipts – and returns a credit decision in under 30 minutes at 97% accuracy. No public training set exists for how Philippine SMEs trade, pay, and borrow. Jia has spent three years building one, sharpened by every loan on its book. With Jia Accounts now live, real-time cashflow data feeds directly into Ossicone’s models, compounding its accuracy over time.

SMEs across emerging markets face an estimated US$8 trillion credit gap that legacy banks are structurally unable to close. Jia is now making the infrastructure it built and proved on its own balance sheet available to the banks, cooperatives, and lending companies that want to close it. Through Ossicone via API and a white-label product, any financial institution can deploy Jia’s accounts, underwriting, and capital connectivity under its own brand, without rebuilding core infrastructure. Netbank is the first institution to build on that infrastructure — pairing the banking rails behind Jia Accounts with Ossicone-powered underwriting — validating a model Jia is now extending to banks, cooperatives, and lending companies across the region.

“Every emerging market has thousands of businesses growing fast, paying on time, and waiting for a bank that can see them clearly,” said Zach Marks, CEO of Jia. “We spent three years building the infrastructure to do that and proving it on our own balance sheet. Now we’re opening it to other institutions, because the opportunity is too large for any one lender to capture alone.”

“There is no public dataset for Philippine SME financial documents. That’s the moat,” said Krizanne Ty, President and Country Head at Jia Philippines. “Every loan has sharpened Ossicone’s accuracy, and now that businesses bank with Jia, their live cashflow feeds directly into the models — making them better for every SME on our book and every institution building on our platform.”

Financial institutions interested in deploying Jia’s infrastructure can reach the team at partners@jia.xyz. 

About Jia

Jia is the financial operating system for emerging market businesses, combining business banking, AI-powered underwriting, and capital connectivity in a single platform. Validated on its own live loan book in the Philippines since 2022, Jia now makes the same infrastructure available for banks, cooperatives, and lending companies to deploy under their own brand. Jia is led by a team that has scaled fintech businesses and managed more than US$10 billion in assets across emerging markets, and is backed by leading global fintech investors. Users can learn more at jia.xyz.

Contact

Partner
Maggie Philbin
VSC for Jia
press@jia.xyz

Nova Junk, a family-owned junk removal company based in Alexandria, Virginia, celebrates two decades of responsible hauling, recycling, and donation services across the Washington DC metro region.

Washington, United States, 16th Jul 2026 – Nova Junk, a locally owned junk removal company serving Washington, DC, Northern Virginia, and Maryland, is marking its 20th year in business. Founded on September 11, 2005, according to information published on the company website, the company has grown from a two-person family operation into a multi-service hauling company with a team that includes extended family members and long-tenured employees.

Nova Junk provides junk removal, estate cleanouts, office cleanouts, construction debris removal, yard debris hauling, shed removal, hot tub disposal, and labor-only services, according to the company website. The company serves communities throughout the Washington DC metro area, including Alexandria, Fairfax, Arlington, Bethesda, Montgomery County, and Prince George County.

A distinguishing feature of Nova Junk’s operating model is its three-stage disposal process: donate, recycle, and landfill. According to information published on the company website, the team sorts through all collected material, first setting aside items that can be donated to local charities and then separating recyclable materials such as batteries, printers, and refrigerators. Only the remainder goes to the landfill, and the company states that it typically sends just one third of collected material to the dump.

The company is licensed and fully insured, according to the company website, and places a strong emphasis on punctuality and transparent pricing. Nova Junk states that final charges are adjusted downward when a load turns out to be smaller than estimated, a policy highlighted repeatedly in customer reviews published on the company website.

“We started this company as a family and grew it the same way – by treating every customer’s home and business the way we would want ours treated,” said Norman Elbekri, Co-founder at Nova Junk. “After 20 years we are still committed to the same values we started with: honest pricing, responsible disposal, and service that people can count on.”

Nova Junk serves both residential and commercial clients. Services extend to de-cluttering and hoarding solutions, moving and foreclosure cleanouts, and demolition site cleanup. The company operates from two locations – 2000 Duke Street in Alexandria, Virginia and Smoketown Road in Woodbridge, Virginia – and can be reached at novajunk.com.

About Nova Junk

Nova Junk is a family-owned junk removal company founded in 2005, serving Washington, DC, Northern Virginia, and Maryland. The company provides residential and commercial hauling, estate cleanouts, construction debris removal, and specialty services including shed and hot tub removal. Nova Junk is committed to responsible disposal through a donate-recycle-landfill approach that minimizes landfill impact. Learn more at https://www.novajunk.com

Media Contact

Organization: Nova Junk

Contact Person: Norman Elbekri Co-founder

Website: https://www.novajunk.com/

Email:
info@novajunk.com

City: Washington

Country:United States

Release id:47175

The post Nova Junk marks 20 years of eco-friendly junk removal in the Washington DC area appeared first on King Newswire. This content is provided by a third-party source.. King Newswire makes no warranties or representations in connection with it. King Newswire is a press release distribution agency and does not endorse or verify the claims made in this release. If you have any complaints or copyright concerns related to this article, please contact the company listed in the ‘Media Contact’ section

Jyong Biotech Ltd. (Nasdaq stock code: MENS) (hereinafter referred to as “the Company” or “Jyong Biotech”) is a science-driven biotechnology company dedicated to developing and commercializing innovative plant-based therapies. The Company recently announced that, following an analysis of the clinical efficacy and competitive advantages of its innovative botanical drugs Botreso® and PCP, it has advanced its market access strategy.

As previously announced by the company, its first core product, Botreso®, has completed four Phase III clinical trials (API-1) in the United States and Taiwan, while its second core product, PCP, has successfully completed a Phase II clinical trial. Overall clinical data demonstrate that Jyong Biotech’s innovative botanical drugs exhibit significant differentiation advantages compared to currently marketed synthetic chemical drugs.

Overall Safety Profile for Long-Term Use

For middle-aged and elderly males requiring long-term medication, safety is one of the most decisive factors. In clinical trials—Botreso® (Phase III) had a treatment duration of one year, while PCP (Phase II) lasted two years—no drug-related serious adverse events were observed, demonstrating excellent safety and tolerability.

In contrast, currently available chemically synthesized drugs for the treatment of benign prostatic hyperplasia (BPH) are often associated with adverse effects such as postural hypotension, erectile dysfunction, and decreased libido. Regulatory authorities and research institutions have linked certain synthetic alternative medications to significant risks, prompting the U.S. Food and Drug Administration (FDA) to issue a safety advisory regarding advanced prostate cancer and depression in 2011, and to include suicidal ideation in its list of adverse reactions in 2022. Additionally, an independent study conducted in 2021 also established associations between these drugs and cardiac failure.

Management of risks associated with advanced prostate cancer

Large-scale international clinical trials have demonstrated that while certain synthetic drugs used to treat benign prostatic hyperplasia (BPH) can reduce the overall incidence of prostate cancer, they may paradoxically increase the proportion of advanced prostate cancer (Grisson score ≥ 7) when cancer develops, thereby posing significant clinical safety concerns.

The Phase II clinical trial of PCP was a large-scale, long-term study on rare conditions conducted in Taiwan across 20 major hospitals. Over a period of two years, the trial involved 135 urologists (representing more than one-tenth of all urologists in Taiwan) and enrolled a total of 702 participants. It was one of the first global clinical trials specifically targeting prostate cancer prevention using a novel botanical drug conducted in Taiwan. The results demonstrated that PCP exhibited a downward trend in both overall prostate cancer incidence and the risk of advanced-stage prostate cancer, effectively addressing concerns within the medical community regarding the risks associated with existing therapies.

Comprehensive approach of “Treatment + Prevention + Metabolic Management”

Based on the clinical data from the company’s conducted trials, the company believes it is establishing a differentiated product positioning.

• Improvement of lower urinary tract symptoms (LUTS): Effectively alleviates symptoms associated with benign prostatic hyperplasia.

• Prevention of prostate cancer: Demonstrates prophylactic clinical potential.

• Metabolic and cardiovascular protection: Decreased triglyceride levels (P=0.05), significantly reduced total cholesterol and low-density lipoprotein (bad cholesterol) (P<0.05), significantly increased high-density lipoprotein (good cholesterol) (P<0.05), and maintained stable blood glucose levels.

This comprehensive therapy delivers benefits without adversely affecting blood pressure, liver function, or renal function. The company emphasizes that this integrated approach combining treatment, prevention, and metabolic management is exceptionally rare among current prostate medications and holds significant appeal for men aged 40 and above.

Technical Barriers and Competitive Advantages

Due to the inherent complexity and diversity of components in novel botanical drugs, quality control poses greater challenges compared to that of small-molecule chemical drugs. Jianyong Biotechnology asserts that the company has successfully established a comprehensive technical platform, which includes:

• Purification and establishment of reference standards.

• Development and validation of analytical methods.

• Perform the validation analysis and verification process.

The company believes that such comprehensive capabilities create substantial market entry barriers, rendering the products highly difficult to replicate. Furthermore, they effectively mitigate risks associated with competition from counterfeit and substandard products as well as generic drugs, ultimately contributing to an extended period of market monopoly.

The upgraded market positioning and strategic value

As a plant-based new drug protected by global patents, Jyong Biotech believes its market strategy leverages the following key advantages:

• Pricing competitiveness: Its unique metabolic protection profile and safety profile enable it to command higher prices compared to non-patented generic drugs, making it attractive to both out-of-pocket and high-end healthcare markets.

• Authorization potential: The combination of high tolerability, excellent safety profile (no serious adverse reactions), and multiple clinical benefits makes it an ideal target for international pharmaceutical collaboration.

• Market scalability: Expanding the product portfolio from treatment-oriented approaches to the fields of preventive medicine and health management.

Globally, over 500 million men aged 50 and above seek treatment for benign prostatic hyperplasia (BPH). In 2020, the global BPH drug market was valued at $4.1 billion and is projected to reach $9.8 billion by 2026. Although the current treatment market generates annual revenues of approximately $6.5 to $7 billion, this figure reflects price reductions due to patent expiration. If calculated based on prices during the patent period, the market potential exceeds $20 billion annually.

“Due to the complex composition of botanical new drugs, they face significant challenges in quality control compared to small-molecule chemical drugs,” stated Chairman Guo of Jianyong Biotechnology. “We have established a robust technical platform that encompasses the purification of reference standards, development and validation of analytical methods, as well as performance validation analyses. This high entry barrier makes counterfeiting difficult to achieve, reduces competition from generic drugs, and helps extend market exclusivity periods.”

Chairman Guo stated: “Botreso® is Taiwan’s first oral botanical drug to obtain an IND approval from the U.S. FDA for Phase III clinical trials (API-1) and has successfully completed all four Phase III clinical trials.”

Jyong Biotech holds multiple invention patents across Asia, the Americas, and the European Union, and has signed letters of intent and investment agreements with several international pharmaceutical companies. The company plans to further expand its strategic, fee-based licensing partnerships to support its global market expansion.

As of today, Botreso® and PCP remain in the investigational new drug candidate stage and have not yet been approved for commercial use in any jurisdiction. Jyong Biotech will comply with applicable regulatory disclosure obligations and provide timely, accurate, and complete updates on significant progress.

Company Profile: Jyong Biotech Ltd., headquartered in Taiwan, is a science-driven biotechnology company dedicated to the research, development, and commercialization of innovative and differentiated novel drugs (of plant origin), with a primary focus on the treatment of urinary system disorders, initially targeting the markets in the United States, the European Union, and Asia. Since its establishment in 2002, the company has developed comprehensive capabilities encompassing all critical stages of drug development, including early-stage drug discovery and development, pharmacology, toxicology, clinical trials, regulatory affairs, manufacturing, and commercialization. Leveraging robust R&D capabilities and proprietary platforms, the company has developed a portfolio of plant-derived candidate drugs, including its lead plant-based candidate Botreso®, another plant-based candidate drug in clinical development, and several other plant-based candidates in preclinical stages. The company is committed to developing and delivering cutting-edge innovative therapeutics to address customer health needs and strives to become a respected and valuable enterprise.

For more information, please contact:

Jyong Biotech Ltd.

ir@jyongbio.com

Investor Relations Department

WFS Investor Relations Inc.

Mailbox: services@wfsir.com

Phone: +1628 283 9214